|
31 Aug 2025 |
Jupiter Life Line
|
Consensus Share Price Target
|
1410.40 |
1754.80 |
- |
24.42 |
buy
|
|
|
|
|
05 Aug 2025
|
Jupiter Life Line
|
Prabhudas Lilladhar
|
1410.40
|
1720.00
|
1410.60
(-0.01%)
|
21.95 |
Buy
|
|
|
JLHL's Q1 consolidated EBITDA grew by 20% YoY (flat QoQ) to Rs781mn, in line with our estimates, aided by higher ARPOB. Its operational efficiency has been strong in the competitive markets of MMR. The company reported revenue/EBITDA CAGR of 20%/25% over FY22-25. Given its expansion plans, scale-up in occupancy and improving margins, growth momentum is expected to sustain over the medium term. We believe strategic greenfield expansions in densely populated micro-markets of western regions will drive sustainable...
|
|
04 Aug 2025
|
Jupiter Life Line
|
Anand Rathi
|
1410.40
|
1750.00
|
1449.80
(-2.72%)
|
24.08 |
Buy
|
|
|
In line with our estimates and the consensus, Jupiter Lifeline Hospital reported healthy Q1 figures, with revenue/EBITDA up 21%/22% y/y. PAT, however, dipped a tad, 1% y/y due to higher interest cost and depreciation charges.
|
|
13 May 2025
|
Jupiter Life Line
|
Prabhudas Lilladhar
|
1410.40
|
1720.00
|
1427.50
(-1.20%)
|
21.95 |
Buy
|
|
|
JLHL's Q4 consolidated EBITDA grew by 26% YoY (4% QoQ) to Rs783mn, largely in line with our estimates, aided by higher ARPOB. Its operational efficiency has been strong in the competitive markets of MMR. The company reported revenue/EBITDA CAGR of 20%/25% over FY22-25. Given its expansion plans, scale-up in occupancy and improving margins, growth momentum is expected to sustain over the medium term. We believe strategic greenfield expansions in densely populated micro-markets of western regions...
|
|
10 Feb 2025
|
Jupiter Life Line
|
Prabhudas Lilladhar
|
1410.40
|
1750.00
|
1561.40
(-9.67%)
|
Target met |
Buy
|
|
|
|
|
10 Feb 2025
|
Jupiter Life Line
|
Anand Rathi
|
1410.40
|
1740.00
|
1561.40
(-9.67%)
|
Target met |
Buy
|
|
|
In line with our estimates and the consensus, Jupiter Lifeline Hospital reported healthy Q3 figures, with revenue/EBITDA/PAT up 18%/21%/20% y/y.
|
|
09 Feb 2025
|
Jupiter Life Line
|
ICICI Securities Limited
|
1410.40
|
1610.00
|
1589.65
(-11.28%)
|
Target met |
Hold
|
|
|
Jupiter Life Line Hospital’s (Jupiter) Q3FY25 result undershot our expectation. Revenue growth of 17.6% was driven by its Pune/Indore hospitals while price hike fuelled modest growth at the Thane hospital. Dombivli (200–220 beds) hospital is likely to commence operations in Q1FY27.
|
|
12 Nov 2024
|
Jupiter Life Line
|
Anand Rathi
|
1410.40
|
1740.00
|
1542.20
(-8.55%)
|
Target met |
Buy
|
|
|
In line with our estimates and consensus, Jupiter Lifeline Hospital reported healthy Q2 figures, with revenue/EBITDA/PAT up23%/23%/53% y/y.
|
|
12 Aug 2024
|
Jupiter Life Line
|
Prabhudas Lilladhar
|
1410.40
|
1475.00
|
1310.60
(7.61%)
|
Target met |
Buy
|
|
|
|
|
18 Sep 2023
|
Jupiter Life Line
|
Ventura
|
1410.40
|
1185.00
|
1075.75
(31.11%)
|
Target met |
Buy
|
|
|
Bolstering presence in the Western region through expansion
|
|
06 Sep 2023
|
Jupiter Life Line
|
HDFC Securities
|
1410.40
|
|
|
|
IPO Note
|
|
|
Issue Snapshot: Issue Open: Sep 06 Sep 08, 2023 Price Band: Rs. 695 735 *Issue Size: 11,824,163 eq sh (Fresh Issue of Rs 542.0 cr + Offer for sale of 4,450,000 eq sh) Reservation for: QIB upto 50% eq sh Non-Institutional atleast 15% eq sh ((including 1/3rd for applications between Rs.2 lakhs to Rs.10 lakhs)) Retail atleast 35% eq sh Face Value: Rs 10 Book value: Rs 64.39 (March 31, 2023) Bid size: - 20 equity shares and in multiples thereof 100% Book built Issue IPO Note - Jupiter Life Line Hospitals Limited
|
|
05 Sep 2023
|
Jupiter Life Line
|
SBI Securities
|
1410.40
|
|
|
|
IPO Subscribe
|
|
|
|
|
05 Sep 2023
|
Jupiter Life Line
|
Ventura
|
1410.40
|
|
|
|
IPO Subscribe
|
|
|
|